---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006845"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T03:13:14.028857+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics raises $87.4M in private placement and acquires cGMP manufacturing facility

## Summary
- Gross proceeds of $87.4M from sale of 92,009,981 shares at $0.95/share; Lantheus to purchase $57.4M.
- Acquired 11,500 sq ft cGMP-compliant facility in Somerset, NJ from Lantheus for Pb-labeled radiopharmaceuticals.
- Net proceeds to fund R&D, clinical trials, manufacturing, and general corporate purposes.
- Registration rights agreement filed to register resale of shares with SEC.
- Facility acquisition is part of a strategic collaboration with Lantheus announced Jan 9, 2024.

## SEC filing metadata
- accession: 0001437749-24-006845
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774924006845/0001437749-24-006845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774924006845/isr20240305_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006845
- JSON: https://secwatch.observer/filing/0001437749-24-006845.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006845.txt

## Key facts
- Material Agreements
  Perspective Therapeutics, Inc. entered into Placement Agency Agreement with Oppenheimer & Co. Inc. valued at 5.85% of the gross proceeds (effective 2024-03-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Oppenheimer & Co. Inc.
  - Value: 5.85% of the gross proceeds
  - Effective: 2024-03-04
  source text: The Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the “Placement Agency Agreement”), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the “Placement Agents”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774924006845/0001437749-24-006845-index.htm
- Material Agreements
  Perspective Therapeutics, Inc. entered into Investment Agreement with certain accredited institutional investors valued at approximately $87.4 million (effective 2024-03-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited institutional investors
  - Value: approximately $87.4 million
  - Effective: 2024-03-04
  source text: On March 4, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain accredited institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), 92,009,981 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for a purchase price of $0.95 per share, representing the closing price of the Common Stock on March 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774924006845/0001437749-24-006845-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.